Executive Stock Sales Announcement Amid Dupixent and EYLEA HD Growth

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) reported that fourth-quarter and full-year 2025 revenues rose just 3% and 1% year-over-year, respectively, but robust growth in Dupixent and EYLEA HD largely offset declines in legacy EYLEA sales.

During 2025, the company repurchased approximately $3.5 billion of its own shares (about KRW 4.6 trillion) and announced a new cash dividend. It also issued its financial guidance for 2026 alongside key R&D, clinical and manufacturing-facility investment plans.

On February 9, its Senior Vice President and Chief Financial Officer each sold several hundred thousand dollars’ worth of common stock—roughly KRW 1 billion and KRW 100 million, respectively—under pre-established Rule 10b5-1 plans. Both executives continue to hold significant equity stakes.

In its official release, Regeneron stated that full-year 2025 revenues reached $14.3 billion (about KRW 18.6 trillion). Dupixent delivered $17.8 billion in global sales (approximately KRW 23 trillion), cementing its role as a core growth driver.

Separate from over $7 billion in previously announced U.S. investments, the company unveiled plans for a new $2 billion manufacturing facility in Saratoga Springs, New York (roughly KRW 2.6 trillion), accelerating capacity expansion to meet future demand.

Regeneron is a major U.S. biopharmaceutical company with an antibody-based portfolio—including Dupixent, the EYLEA franchise and Libtayo—expanding its blockbuster lineup in immunology, ophthalmology and oncology.

Despite heightened competition and a high-interest-rate environment, the global biopharma industry continues to pursue balanced strategies of new-drug pipeline development, manufacturing expansion, share repurchases and dividends, keeping large-cap capital allocation and investment themes under close watch.